Tests short-course radiotherapy for locally advanced pancreatic cancer
Tests high-dose short-course particle radiotherapy in adults with locally advanced pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)
Key facts
- Where
- Wiener Neustadt, AustriaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you pregnant or breastfeeding?
Source: NCT05191940, who can take part
Where in Austria
- EBG MedAustron GmbHWiener Neustadt, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- EBG MedAustron GmbH
- Trial code
- NCT05191940
- Record updated
- 20 March 2026
- Original description
This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.Read full original descriptionShow less
Phase II Trial of Hypo-fractionated Highly Conformal Radiotherapy for Locally Advanced Pancreatic Carcinomas
This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
Inclusion: The patient has histologically or cytological confirmed diagnosis of pancreatic cancer (cases with radiological findings suspicious of pancreatic cancer AND elevated CA 19-9 may be enrolled even without positive cytology); The patient is not candidate for radical surgical resection because of one or more of the following reasons:; the patient is staged as locally advanced and with unresectable disease according to the international consensus definition. Specific criteria are: there is involvement of portal vein/superior mesenteric vein with bilateral narrowing/occlusion, exceeding the inferior border of the duodenum; or tumor contact/invasion of 180 or more degree of the superior mesenteric artery or of the truncus coeliacus; or tumor contact/invasion of the proper hepatic artery/ celiac artery; or tumor contact or invasion of the aorta; the patient is not a candidate for radical surgery because of radiographic or biochemical (CA 19-9) progression during neoadjuvant chemotherapy despite being initially classified as resectable or borderline resectable according to the international consensus definition; the patient is not candidate for radical surgery because of cN+ stage; The patient is not candidate to (further) neoadjuvant chemotherapy because of one or more of the following reasons:; the patient is not fit for chemotherapy; the patient has progressed under chemotherapy; the patient has received neoadjuvant chemotherapy but is judged still not a candidate for explorative surgery; Negative staging for distant metastasis; Age > 18 years; Karnofsky index ≥ 70; No tumor infiltration of stomach or duodenum; The patient is informed of the diagnosis and is able to give informed consent (Ability of patient to understand character and individual consequences of the study protocol); Women of fertile age must have adequate conception prevention measures and must not breast feed; Signed Informed Consent (must be available before study inclusion).
Exclusion: Previous abdominal radiotherapy; Major medical or psychiatric comorbidities that contraindicate radiotherapy; Metallic prosthesis or other conditions - IF it prevents an adequate imaging for target volume definition or treatment planning at the discretion of the treating institution contraindicate radiotherapy e.g. active infections in the area; Severe hepatic or renal impairment at discretion of treating institution; Non-exocrine tumors; Presence of distant metastasis; Pregnancy or unwilling to do adequate conception prevention; Lactating and unwilling to discontinue lactation; Men of procreative potential not willing to use effective means of contraception; Patient refusal.